Status:
TERMINATED
Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Type 2 Diabetes Mellitus
Hypertension
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The study will assess the efficacy and tolerability of MK0736 in patients with Type 2 Diabetes Mellitus and Hypertension who are on ongoing therapy with Angiotensin-Converting Enzyme or Angiotensin Re...
Eligibility Criteria
Inclusion
- Must be 18 to 75 years of age
- Type 2 Diabetes Mellitus (Glycohemoglobin \[A1CHbA1c\]: 7 to 10%)
- Hypertension: Diastolic blood pressure (DBP; 85 to 99 mm Hg) and systolic blood pressure (SBP; 120 to 159 mm Hg)
- LDL-C \< 140 mg/dL
- On stable treatment with an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Exclusion
- History of Type I Diabetes mellitus or ketoacidosis
- Patients taking 3 or more blood pressure lowering medications
- Have severe chronic heart failure
- History of certain diseases or conditions such as cardiac arrhythmias, heart attack, stroke, unstable angina, or decompensated vascular disease
- History of cancer within the last 5 years
- Human immunodeficiency virus (HIV) Positive
- Have received treatment with any investigational drugs within the past 30 days
- History of alcohol or drug abuse within the past 3 years
- Body Mass Index ( BMI) \>= 41 kg/m2
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
620 Patients enrolled
Trial Details
Trial ID
NCT00806585
Start Date
December 1 2008
End Date
June 1 2010
Last Update
September 21 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.